eligibility_summary
Eligible: 16–80 years, ≥40 kg, ECOG 0–1, adequate organ function. Advanced clear cell RCC, mesothelioma, or osteosarcoma with CD70+ tumor (≥10% RCC/meso, ≥1% osteo) and measurable/evaluable disease. Prior therapy: RCC stage IV after PD‑1/PD‑L1 plus anti‑angiogenic TKI, mesothelioma/osteosarcoma progressive after standard therapy. Washouts: ≥2 weeks from chemo/TKI, ≥3 months from cell therapy. Exclude: unresolved ≥G2 toxicity, active infection, HBV/HCV, uncontrolled HIV, active autoimmune/neuro/CNS disease, major cardiac/QTc>470 ms, recent surgery, steroids/immunosuppression, prior anti‑CD70, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: CAR.70/IL15-transduced cord blood–derived NK cells (allogeneic, genetically engineered cell therapy) plus lymphodepleting chemotherapy with fludarabine phosphate (purine analog antimetabolite) and cyclophosphamide (alkylating agent). Mechanisms: NK cells are engineered with a CAR that binds CD70 (CD27 ligand) on tumors, triggering antigen-specific NK activation and cytotoxicity, IL-15 transgene provides autocrine support for NK survival, proliferation, and persistence. Fludarabine/cyclophosphamide deplete host lymphocytes to enhance engraftment and activity. Targets: CD70-expressing tumor cells in advanced clear cell RCC, mesothelioma, and osteosarcoma, immune pathways include CAR-driven NK activation, IL-15 signaling, and perforin/granzyme-mediated killing.